Johnson & Johnson (JNJ) Stock May Trade At A Discount As Europe Backs Tecvayli
Johnson & Johnson stock has delivered a 3 year total return of 80.4%, yet the latest valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value pointing to upside while market based multiples suggest the shares are not cheap.
- The 80.4% gain over the past 3 years points to strong shareholder rewards that may already reflect a lot of optimism in Johnson & Johnson.
- Recent approvals for TECVAYLI in Europe and IMAAVY in the US can support long term cash flow expectations, while ongoing talc related litigation remains a key risk that may weigh on how investors price the stock.
- A value score of 3 out of 6 signals a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether Johnson & Johnson’s current share price already captures this blend of growth potential and legal risk or still sits below a reasonable intrinsic value estimate.
Scan for other healthcare stocks showing a similar blend of strong returns, legal overhangs, and cash flow potential by reviewing the hand picked solid balance sheet and fundamentals stocks screener (52 results) in one place.
Is Johnson & Johnson Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model uses projected free cash flows and a required return to estimate what Johnson & Johnson stock might be worth today. For Johnson & Johnson, the model uses last twelve month free cash flow of about $21.7b and assumes those cash flows keep growing rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity approach arrives at an estimated intrinsic value of about $364 per share.
This compares with a current share price that is about 27.0% below that intrinsic value estimate. On this cash flow view, the stock appears undervalued relative to the model’s estimate. The recent FDA approval for IMAAVY as the first treatment for warm autoimmune hemolytic anemia helps explain why the DCF model incorporates ongoing cash generation, even as talc litigation remains a concern that can affect sentiment.
On this Discounted Cash Flow view, Johnson & Johnson stock screens as undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 27.0%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.
Does Johnson & Johnson Look Pricey on Earnings?
P/E is a useful cross check for Johnson & Johnson because earnings are a key focus for large, diversified healthcare groups. Johnson & Johnson currently trades on a P/E of about 30.5x. That is higher than the Pharmaceuticals industry average P/E of about 16.6x, yet below the broader peer average of about 51.4x.
The industry comparison points to Johnson & Johnson being priced at a premium to the typical pharmaceutical stock on earnings. That kind of gap can reflect the scale of the business and its established portfolio, but it also means investors are paying more for each dollar of current earnings than the sector on average. The talc litigation overhang highlighted by the recent Louisiana jury verdict adds another layer of risk that investors need to weigh against this higher earnings multiple.
Overall, Johnson & Johnson stock appears expensive on the P/E multiple relative to the wider pharmaceuticals industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Johnson & Johnson Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this Johnson & Johnson valuation puzzle leaves off. Each one spells out the specific mix of growth, margin and earnings assumptions that would need to hold for Johnson & Johnson’s stock to be worth materially more or less than today’s price, and each links its number to a clear view on how growth, profitability and key risks might evolve over time so you can revisit the logic as new information appears.
Community views on Johnson & Johnson are split between a balanced growth story and a more cautious assessment of what is already priced in.
Bull case: roughly fairly valued
"Recent acquisitions, such as Intra-Cellular Therapies, are expected to contribute substantial revenue streams, with products like CAPLYTA potentially reaching over $5 billion in peak sales, positively affecting the company’s revenue and EPS in the future…"
Read the full Bull Case to see why Johnson & Johnson could be undervalued
Bear case: 8% overvalued
"At ~22× earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow…"
Read the full Bear Case to see why Johnson & Johnson could be overvalued
Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!
The Bottom Line
The Discounted Cash Flow (DCF) view suggests Johnson & Johnson screens as undervalued, while the earnings multiple points to the stock being overvalued relative to the wider pharmaceuticals industry. That split reflects a cash flow story that looks supportive on one hand, and a richer P/E that bakes in higher expectations and sentiment on the other. Broader valuation checks look mixed. The key question is whether current cash flow strength and new drug approvals outweigh the talc litigation risk that could justify a sustained premium or keep a lid on the multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com